Prognostic value of artificial intelligence-derived echocardiographic measurements in transthyretin cardiomyopathy

Competing Interest Statement

Walser: No disclosures. Flammer: Dr. Flammer has received personal fees from Alnylam, Pfizer, AstraZeneca, Bayer and is national coordinator of the Alexion/AstraZeneca sponsored DepleTTR-CM study. He received amyloidosis related grant funding from the Swiss National Science Foundation (Project 320030-236299). Hundertmark: No disclosures. Shiri: No disclosures. Ciocca: No disclosures. Ryffel: No disclosures. De Marchi: No disclosures. Schwotzer: Dr. Schwotzer received personal fees from Alnylam, AstraZeneca, Johnson&Johnson. As the coordinator of the Swiss Amyloidosis Registry she received financial support from Alnylam, AstraZeneca, Bayer Healthcare, SOBI and Pfizer. She received amyloidosis related grant funding from Mach-Gaensslen Foundation. Ruschitzka: No disclosures. Tanner: No disclosures. Graeni: Dr Graeni received research funding from the Swiss National Science Foundation, InnoSuisse, Center for Artificial Intelligence in Medicine University Bern, Novartis Foundation for Medical-Biological Research, Swiss Heart Foundation, Schmieder-Bohrisch Foundation, Gottfried, and Julia Bangerter-Rhyner Foundation, the GAMBIT, outside of the submitted work; furthermore, funding to the institution was received from Alnylam Pharmaceuticals, AstraZeneca, Pfizer, Bayer, outside of the submitted work and without impact on Dr. Graeni's personal remuneration. Benz: Dr. Benz reports a career development grant from the Advanced Clinician Scientist Program University Medicine Zurich UMZH; research funding from the Swiss Heart Foundation, Olga Mayenfisch Stiftung and Immanuel und Ilse Straub Stiftung; investigator-initiated research funding from AstraZeneca and Life Molecular Imaging/Lantheus; consulting fees from Pfizer, Alnylam, Bayer Healthcare and AstraZeneca; travel support from Philips.

Funding Statement

The study was supported by an investigator-initiated grant from Astra Zeneca to fund automated measurements by Us2.ai. The company had no involvement in the design, conduct, analysis, or reporting of the study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Zurich Cantonal Ethics Committee (KEK-ZH 2014-0490) as well as the Bern Cantonal Ethics Committee (KEK: 2021-00135).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes